Table 3. SUCRA values for three outcomes.
| Outcome | Treatment | SUCRA |
|---|---|---|
| OS | Pem + CT | 0.98 |
| Pem | 0.70 | |
| Ate + Bev + CT | 0.67 | |
| Dur | 0.65 | |
| Ate + CT | 0.49 | |
| Dur + Tre | 0.48 | |
| Ipi + CT | 0.47 | |
| Bev + CT | 0.25 | |
| CT | 0.17 | |
| Niv | 0.13 | |
| PFS | Pem + CT | 0.96 |
| Ate + CT | 0.80 | |
| Niv + CT | 0.62 | |
| Pem | 0.55 | |
| Ipi + CT | 0.53 | |
| Niv + Ipi | 0.49 | |
| Dur + Tre | 0.22 | |
| CT | 0.21 | |
| Niv | 0.12 | |
| SAEs | Niv | 0.07 |
| Dur | 0.11 | |
| Pem | 0.12 | |
| Dur + Tre | 0.31 | |
| Niv + CT | 0.36 | |
| Niv + Ipi | 0.41 | |
| CT | 0.55 | |
| Pem + CT | 0.62 | |
| Ate + CT | 0.76 | |
| Ipi + CT | 0.83 | |
| Bev + CT | 0.87 | |
| Ate + Bev + CT | 0.98 |
SUCRA, the surfaces under the cumulative ranking curve; OS, overall survival; PFS, progression-free survival; SAEs, serious adverse events; Pem, pembrolizumab; Ate, atezolizumab; Bev, bevacizumab; Dur, durvalumab; Ipi, ipilimumab; Niv, nivolumab; Tre, tremelimumab; CT, chemotherapy.